Efficacy of Roghan-e-Kalonji (Nigella sativa oil) in the Treatment of Primary Hyperlipidaemia
M. Nazim, *B.D. Khan, Misbahuddin Siddiqui and M. Shoaib
Hippocratic Journal of Unani Medicine
Hippocratic Journal of Unani Medicine July - September 2014, Vol. 9 No. 3, Pages 39-48
Hyperlipidaemia is an important factor for the development of atherosclerotic lesion which is responsible for various complications such as ischemic heart diseases, cerebrovascular diseases and hypertension etc. These complications are major cause of mortality and morbidity. The association of Hyperlipidaemia with development of atherosclerotic lesion has prompted the researchers of various field of medicine to develop safe and efficacious drug for the management of Hyperlipidaemia. Although, a number of plant origin hypolipidaemic drugs have been screened for hypolipidaemic activity but none of them offers convincing treatment. In Unani system Medicine a large number of drugs are reported to possess possible treatment for some metabolic diseases particularly obesity (Saman-e-Mufrat) and its related complications. Most of these drugs have not been subjected for evaluation on scientific parameters. Keeping these facts in mind, a single blind standard controlled non randomized trial was planned to evaluate the efficacy of a Roghane Kalonji (Nigella sativa oil) in the management of primary hyperlipidaemia.
The present study was conducted on 60 diagnosed patients of primary hyperlipidaemia at Ajmal Khan Tibbiya College Hospital, Aligarh Muslim University Aligarh. The patients were allocated in two groups. Group A (Test group) comprising of 40 patients and Group ‘B’ (Placebo group) comprising of 20 patients. In group ‘A’ the Roghane Kalonji in the dose of 6 ml twice a day was given whereas in group ’B’ Atrovastatin in the dose of 10 mg once a day was administered for 3 months. The subjective and the objective parameters (lipid profile) were assessed on 0, 15th, 30th, 60th, 90th days. The test drug was found to be statistically significant in lowering serum cholesterol and serum triglyceride level in the patients of Hyperlipidaemia (p<0.05).